The latest price target for Zymeworks (NASDAQ:ZYME) was reported by HC Wainwright & Co. on September 18, 2024. The analyst firm set a price target for $10.00 expecting ZYME to fall to within 12 months (a possible -23.61% downside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Zymeworks (NASDAQ:ZYME) was provided by HC Wainwright & Co., and Zymeworks reiterated their neutral rating.

The last upgrade for Zymeworks Inc happened on December 20, 2022 when Jefferies raised their price target to $11. Jefferies previously had a hold for Zymeworks Inc.

The last downgrade for Zymeworks Inc happened on November 1, 2022 when HC Wainwright & Co. changed their price target from $40 to $8 for Zymeworks Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zymeworks, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zymeworks was filed on September 18, 2024 so you should expect the next rating to be made available sometime around September 18, 2025.

While ratings are subjective and will change, the latest Zymeworks (ZYME) rating was a reiterated with a price target of $10.00 to $10.00. The current price Zymeworks (ZYME) is trading at is $13.09, which is out of the analyst’s predicted range.